Last reviewed · How we verify
DRSP-EE
DRSP-EE is a combined oral contraceptive containing drospirenone (a progestin) and ethinyl estradiol (an estrogen) that prevents ovulation and alters cervical mucus to inhibit fertilization.
DRSP-EE is a combined oral contraceptive containing drospirenone (a progestin) and ethinyl estradiol (an estrogen) that prevents ovulation and alters cervical mucus to inhibit fertilization. Used for Contraception (prevention of pregnancy), Treatment of acne vulgaris (in females), Treatment of premenstrual dysphoric disorder (PMDD).
At a glance
| Generic name | DRSP-EE |
|---|---|
| Also known as | Yasmin, SCH 900121 |
| Sponsor | Organon and Co |
| Drug class | Oral contraceptive (combined hormonal contraceptive) |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | Phase 3 |
Mechanism of action
Drospirenone is a fourth-generation progestin with antimineralocorticoid activity, while ethinyl estradiol is a synthetic estrogen. Together, they suppress the luteinizing hormone (LH) surge needed for ovulation and increase cervical mucus viscosity to prevent sperm penetration. The progestin component also alters the endometrium to reduce implantation likelihood.
Approved indications
- Contraception (prevention of pregnancy)
- Treatment of acne vulgaris (in females)
- Treatment of premenstrual dysphoric disorder (PMDD)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
- International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
- Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (PHASE1)
- A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants (PHASE1)
- A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DRSP-EE CI brief — competitive landscape report
- DRSP-EE updates RSS · CI watch RSS
- Organon and Co portfolio CI